Navigating the complexities of the NSCLC treatment pathway: A focus on antibody-drug conjugates
touchPANEL DISCUSSION for touchONCOLOGY
Listen to a panel of leading experts discuss the emerging role of antibody-drug conjugates (ADCs) in the treatment of patients with non-small cell lung cancer (NSCLC), including the mechanistic rationale and role of biomarkers in patient selection, the latest efficacy and safety data, and dose-finding strategies for optimal use in NSCLC.
The experts:
Prof. Jarushka Naidoo, Beaumont RCSI Cancer Centre, Dublin, Ireland
Dr Rebecca Heist, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Dr Antonio Passaro, European Institute of Oncology, Milan…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.